Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,548 followers.

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma https://t.co/JBpVBtVUh9 https://t.co/3V3z3r012d

12 Jan 2023

Reply Repost Favourite

New research: Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma: In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in… https://t.co/

10 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.